AstraZeneca PLC (AZN)
After hours:
| Previous close | 58.10 |
| Open | 58.20 |
| Bid | 58.88 x 3000 |
| Ask | 59.00 x 900 |
| Day's range | 58.17 - 58.99 |
| 52-week range | 46.48 - 64.21 |
| Volume | |
| Avg. volume | 4,544,917 |
| Market cap | 182.364B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 108.68 |
| EPS (TTM) | 0.54 |
| Earnings date | N/A |
| Forward dividend & yield | 1.40 (2.41%) |
| Ex-dividend date | 12 Aug 2021 |
| 1y target est | 67.68 |
- Zacks
AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron
Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.
- Business Wire
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
WILMINGTON, Del., January 13, 2022--AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionize cancer care at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).
- Business Wire
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
WILMINGTON, Del., January 13, 2022--AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US. TEZSPIRE was approved by the US Food and Drug Administration (FDA) on December 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.1
